Prevention of cardioembolic stroke in patients with atrial fibrillation

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia.
• AF significantly increases stroke risk, particularly in older adults.
• Effective stroke prevention is crucial for managing AF patients.

Purpose of the Study:

• To provide an overview and update on stroke prevention strategies for AF patients.
• To compare the efficacy and safety of different antithrombotic therapies.
• To evaluate the role of interventional procedures in stroke risk reduction.

Main Methods:

• Review of current literature on primary and secondary stroke prevention in AF.
• Comparison of Vitamin K antagonists (VKAs), aspirin, aspirin/clopidogrel combination, and direct thrombin inhibitors.
• Assessment of evidence for interventional therapies like left atrial appendage closure and catheter ablation.

Main Results:

• VKAs are the established treatment for high-risk AF patients.
• Aspirin monotherapy and dual antiplatelet therapy are less effective than VKAs in AF.
• Dabigatran demonstrates non-inferior efficacy to warfarin with a notable reduction in bleeding events.
• Interventional procedures have not yet demonstrated stroke risk reduction in AF.

Conclusions:

• Vitamin K antagonists remain a cornerstone for stroke prevention in AF.
• Direct thrombin inhibitors, such as dabigatran, offer a safe and effective alternative to VKAs.
• Current evidence does not support interventional therapies for stroke risk reduction in AF.